25 XP   0   0   10

Xvivo Perfusion AB
Buy, Hold or Sell?

Let's analyse Xvivo Perfusion AB together

PenkeI guess you are interested in Xvivo Perfusion AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Xvivo Perfusion AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Xvivo Perfusion AB

I send you an email if I find something interesting about Xvivo Perfusion AB.

Quick analysis of Xvivo Perfusion AB (30 sec.)










What can you expect buying and holding a share of Xvivo Perfusion AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr61.75
Expected worth in 1 year
kr78.10
How sure are you?
75.0%

+ What do you gain per year?

Total Gains per Share
kr16.35
Return On Investment
5.9%

For what price can you sell your share?

Current Price per Share
kr275.00
Expected price per share
kr217.00 - kr343.50
How sure are you?
50%

1. Valuation of Xvivo Perfusion AB (5 min.)




Live pricePrice per Share (EOD)

kr275.00

Intrinsic Value Per Share

kr4.96 - kr183.56

Total Value Per Share

kr66.71 - kr245.30

2. Growth of Xvivo Perfusion AB (5 min.)




Is Xvivo Perfusion AB growing?

Current yearPrevious yearGrowGrow %
How rich?$182.8m$128.2m$32.1m20.0%

How much money is Xvivo Perfusion AB making?

Current yearPrevious yearGrowGrow %
Making money$2.1m$433k$1.7m79.9%
Net Profit Margin15.0%4.8%--

How much money comes from the company's main activities?

3. Financial Health of Xvivo Perfusion AB (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#114 / 340

Most Revenue
#171 / 340

Most Profit
#87 / 340

What can you expect buying and holding a share of Xvivo Perfusion AB? (5 min.)

Welcome investor! Xvivo Perfusion AB's management wants to use your money to grow the business. In return you get a share of Xvivo Perfusion AB.

What can you expect buying and holding a share of Xvivo Perfusion AB?

First you should know what it really means to hold a share of Xvivo Perfusion AB. And how you can make/lose money.

Speculation

The Price per Share of Xvivo Perfusion AB is kr275.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xvivo Perfusion AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xvivo Perfusion AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr61.75. Based on the TTM, the Book Value Change Per Share is kr4.09 per quarter. Based on the YOY, the Book Value Change Per Share is kr3.44 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xvivo Perfusion AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.200.1%0.070.0%0.010.0%0.010.0%0.010.0%
Usd Book Value Change Per Share0.050.0%0.380.1%0.320.1%0.210.1%0.140.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.050.0%0.380.1%0.320.1%0.210.1%0.140.1%
Usd Price Per Share30.97-27.06-18.82-22.61-14.78-
Price to Earnings Ratio37.89-366.74-707.14--108.51--196.85-
Price-to-Total Gains Ratio613.06-315.41-102.73-432.84-633.56-
Price to Book Ratio5.34-5.37-4.66-7.63-7.65-
Price-to-Total Gains Ratio613.06-315.41-102.73-432.84-633.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share25.85
Number of shares38
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.380.21
Usd Total Gains Per Share0.380.21
Gains per Quarter (38 shares)14.607.96
Gains per Year (38 shares)58.3931.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10584803222
2011710606454
3017516409686
402342220127118
502922800159150
603503380191182
704093960223214
804674540255246
905265120287278
1005845700319310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%13.07.00.065.0%27.013.00.067.5%32.014.00.069.6%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%15.05.00.075.0%30.010.00.075.0%35.010.01.076.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share4.00.00.0100.0%10.02.00.083.3%15.05.00.075.0%30.010.00.075.0%35.010.01.076.1%

Fundamentals of Xvivo Perfusion AB

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Fundamental data was last updated by Penke on 2024-03-13 21:08:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Xvivo Perfusion AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xvivo Perfusion AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A Net Profit Margin of 44.0% means that kr0.44 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Xvivo Perfusion AB:

  • The MRQ is 44.0%. The company is making a huge profit. +2
  • The TTM is 15.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ44.0%TTM15.0%+29.0%
TTM15.0%YOY4.8%+10.2%
TTM15.0%5Y-0.5%+15.5%
5Y-0.5%10Y1.8%-2.3%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ44.0%-10.6%+54.6%
TTM15.0%-20.2%+35.2%
YOY4.8%-14.0%+18.8%
5Y-0.5%-19.5%+19.0%
10Y1.8%-23.8%+25.6%
1.1.2. Return on Assets

Shows how efficient Xvivo Perfusion AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • 3.1% Return on Assets means that Xvivo Perfusion AB generated kr0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Xvivo Perfusion AB:

  • The MRQ is 3.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.1%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.1%TTM1.1%+2.0%
TTM1.1%YOY0.3%+0.8%
TTM1.1%5Y0.1%+1.0%
5Y0.1%10Y0.3%-0.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1%-3.0%+6.1%
TTM1.1%-4.2%+5.3%
YOY0.3%-4.0%+4.3%
5Y0.1%-3.8%+3.9%
10Y0.3%-4.1%+4.4%
1.1.3. Return on Equity

Shows how efficient Xvivo Perfusion AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • 3.5% Return on Equity means Xvivo Perfusion AB generated kr0.04 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Xvivo Perfusion AB:

  • The MRQ is 3.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.5%TTM1.3%+2.3%
TTM1.3%YOY0.3%+0.9%
TTM1.3%5Y0.1%+1.1%
5Y0.1%10Y0.3%-0.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5%-3.5%+7.0%
TTM1.3%-4.4%+5.7%
YOY0.3%-4.7%+5.0%
5Y0.1%-5.7%+5.8%
10Y0.3%-6.2%+6.5%

1.2. Operating Efficiency of Xvivo Perfusion AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xvivo Perfusion AB is operating .

  • Measures how much profit Xvivo Perfusion AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • An Operating Margin of -16.2% means the company generated kr-0.16  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Xvivo Perfusion AB:

  • The MRQ is -16.2%. The company is operating very inefficient. -2
  • The TTM is -7.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-16.2%TTM-7.2%-8.9%
TTM-7.2%YOY-1.7%-5.5%
TTM-7.2%5Y-6.4%-0.9%
5Y-6.4%10Y-2.0%-4.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.2%-24.5%+8.3%
TTM-7.2%-14.9%+7.7%
YOY-1.7%-11.5%+9.8%
5Y-6.4%-17.1%+10.7%
10Y-2.0%-20.6%+18.6%
1.2.2. Operating Ratio

Measures how efficient Xvivo Perfusion AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 1.16 means that the operating costs are kr1.16 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 1.162. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.005. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.162TTM1.005+0.156
TTM1.005YOY0.988+0.017
TTM1.0055Y1.047-0.042
5Y1.04710Y0.994+0.053
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1621.454-0.292
TTM1.0051.452-0.447
YOY0.9881.434-0.446
5Y1.0471.432-0.385
10Y0.9941.366-0.372

1.3. Liquidity of Xvivo Perfusion AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xvivo Perfusion AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 6.14 means the company has kr6.14 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 6.145. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.843. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.145TTM4.843+1.301
TTM4.843YOY5.720-0.877
TTM4.8435Y5.605-0.762
5Y5.60510Y5.745-0.140
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1452.789+3.356
TTM4.8432.793+2.050
YOY5.7203.586+2.134
5Y5.6053.492+2.113
10Y5.7453.450+2.295
1.3.2. Quick Ratio

Measures if Xvivo Perfusion AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A Quick Ratio of 5.09 means the company can pay off kr5.09 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 5.092. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.846. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.092TTM3.846+1.246
TTM3.846YOY4.735-0.888
TTM3.8465Y4.654-0.808
5Y4.65410Y4.616+0.038
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0921.587+3.505
TTM3.8461.633+2.213
YOY4.7352.185+2.550
5Y4.6542.300+2.354
10Y4.6162.255+2.361

1.4. Solvency of Xvivo Perfusion AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xvivo Perfusion AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xvivo Perfusion AB to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.11 means that Xvivo Perfusion AB assets are financed with 10.8% credit (debt) and the remaining percentage (100% - 10.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 0.108. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.144. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.108TTM0.144-0.035
TTM0.144YOY0.158-0.014
TTM0.1445Y0.125+0.018
5Y0.12510Y0.113+0.012
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1080.400-0.292
TTM0.1440.386-0.242
YOY0.1580.330-0.172
5Y0.1250.440-0.315
10Y0.1130.460-0.347
1.4.2. Debt to Equity Ratio

Measures if Xvivo Perfusion AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A Debt to Equity ratio of 12.1% means that company has kr0.12 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 0.121. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.168. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.121TTM0.168-0.047
TTM0.168YOY0.188-0.019
TTM0.1685Y0.145+0.024
5Y0.14510Y0.130+0.015
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1210.566-0.445
TTM0.1680.569-0.401
YOY0.1880.479-0.291
5Y0.1450.626-0.481
10Y0.1300.692-0.562

2. Market Valuation of Xvivo Perfusion AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Xvivo Perfusion AB generates.

  • Above 15 is considered overpriced but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A PE ratio of 37.89 means the investor is paying kr37.89 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Xvivo Perfusion AB:

  • The EOD is 31.626. Based on the earnings, the company is overpriced. -1
  • The MRQ is 37.894. Based on the earnings, the company is overpriced. -1
  • The TTM is 366.739. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD31.626MRQ37.894-6.268
MRQ37.894TTM366.739-328.845
TTM366.739YOY707.138-340.399
TTM366.7395Y-108.514+475.253
5Y-108.51410Y-196.847+88.333
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD31.626-1.038+32.664
MRQ37.894-1.216+39.110
TTM366.739-1.757+368.496
YOY707.138-2.582+709.720
5Y-108.514-1.553-106.961
10Y-196.847-1.463-195.384
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Xvivo Perfusion AB:

  • The EOD is 119.461. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 143.136. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 111.652. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD119.461MRQ143.136-23.675
MRQ143.136TTM111.652+31.484
TTM111.652YOY-295.905+407.556
TTM111.6525Y433.431-321.779
5Y433.43110Y239.501+193.930
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD119.461-1.207+120.668
MRQ143.136-1.746+144.882
TTM111.652-2.961+114.613
YOY-295.905-6.143-289.762
5Y433.431-4.928+438.359
10Y239.501-5.626+245.127
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xvivo Perfusion AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 5.34 means the investor is paying kr5.34 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Xvivo Perfusion AB:

  • The EOD is 4.454. Based on the equity, the company is fair priced.
  • The MRQ is 5.336. Based on the equity, the company is overpriced. -1
  • The TTM is 5.373. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.454MRQ5.336-0.883
MRQ5.336TTM5.373-0.037
TTM5.373YOY4.660+0.713
TTM5.3735Y7.630-2.257
5Y7.63010Y7.650-0.020
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD4.4542.038+2.416
MRQ5.3362.321+3.015
TTM5.3732.444+2.929
YOY4.6603.028+1.632
5Y7.6303.918+3.712
10Y7.6504.245+3.405
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Xvivo Perfusion AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5374.087-87%3.436-84%2.230-76%1.467-63%
Book Value Per Share--61.74854.155+14%43.312+43%34.617+78%22.397+176%
Current Ratio--6.1454.843+27%5.720+7%5.605+10%5.745+7%
Debt To Asset Ratio--0.1080.144-25%0.158-31%0.125-14%0.113-4%
Debt To Equity Ratio--0.1210.168-28%0.188-35%0.145-16%0.130-7%
Dividend Per Share----0%-0%-0%-0%
Eps--2.1740.729+198%0.146+1386%0.122+1682%0.084+2479%
Free Cash Flow Per Share--0.5760.179+221%0.221+160%-0.263+146%-0.184+132%
Free Cash Flow To Equity Per Share--0.4573.501-87%0.167+174%1.485-69%1.112-59%
Gross Profit Margin--1.000-9.045+1004%-19.199+2020%-2.286+329%3.378-70%
Intrinsic Value_10Y_max--183.556--------
Intrinsic Value_10Y_min--4.961--------
Intrinsic Value_1Y_max--2.354--------
Intrinsic Value_1Y_min---0.529--------
Intrinsic Value_3Y_max--19.297--------
Intrinsic Value_3Y_min---0.710--------
Intrinsic Value_5Y_max--50.977--------
Intrinsic Value_5Y_min--0.074--------
Market Cap8662362500.000-20%10379085250.0009067918562.500+14%6307774875.000+65%7704184160.000+35%5015053620.000+107%
Net Profit Margin--0.4400.150+193%0.048+813%-0.005+101%0.018+2326%
Operating Margin---0.162-0.072-55%-0.017-89%-0.064-61%-0.020-87%
Operating Ratio--1.1621.005+16%0.988+18%1.047+11%0.994+17%
Pb Ratio4.454-20%5.3365.373-1%4.660+15%7.630-30%7.650-30%
Pe Ratio31.626-20%37.894366.739-90%707.138-95%-108.514+386%-196.847+619%
Price Per Share275.000-20%329.500287.875+14%200.250+65%240.555+37%157.198+110%
Price To Free Cash Flow Ratio119.461-20%143.136111.652+28%-295.905+307%433.431-67%239.501-40%
Price To Total Gains Ratio511.658-20%613.059315.408+94%102.730+497%432.842+42%633.562-3%
Quick Ratio--5.0923.846+32%4.735+8%4.654+9%4.616+10%
Return On Assets--0.0310.011+183%0.003+984%0.001+2763%0.003+1030%
Return On Equity--0.0350.013+177%0.003+929%0.001+2431%0.003+990%
Total Gains Per Share--0.5374.087-87%3.436-84%2.230-76%1.467-63%
Usd Book Value--182834230.000160349782.500+14%128244435.000+43%103853841.400+76%66993572.050+173%
Usd Book Value Change Per Share--0.0510.384-87%0.323-84%0.210-76%0.138-63%
Usd Book Value Per Share--5.8045.091+14%4.071+43%3.254+78%2.105+176%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.2040.069+198%0.014+1386%0.011+1682%0.008+2479%
Usd Free Cash Flow--1704032.000530818.000+221%654616.000+160%-877457.100+151%-593753.350+135%
Usd Free Cash Flow Per Share--0.0540.017+221%0.021+160%-0.025+146%-0.017+132%
Usd Free Cash Flow To Equity Per Share--0.0430.329-87%0.016+174%0.140-69%0.105-59%
Usd Market Cap814262075.000-20%975634013.500852384344.875+14%592930838.250+65%724193311.040+35%471415040.280+107%
Usd Price Per Share25.850-20%30.97327.060+14%18.824+65%22.612+37%14.777+110%
Usd Profit--6436556.0002157770.000+198%433034.500+1386%374134.100+1620%255957.300+2415%
Usd Revenue--14639560.00014042237.000+4%9759362.000+50%7858019.300+86%5525444.550+165%
Usd Total Gains Per Share--0.0510.384-87%0.323-84%0.210-76%0.138-63%
 EOD+4 -4MRQTTM+24 -10YOY+25 -95Y+24 -1010Y+22 -12

3.2. Fundamental Score

Let's check the fundamental score of Xvivo Perfusion AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1531.626
Price to Book Ratio (EOD)Between0-14.454
Net Profit Margin (MRQ)Greater than00.440
Operating Margin (MRQ)Greater than0-0.162
Quick Ratio (MRQ)Greater than15.092
Current Ratio (MRQ)Greater than16.145
Debt to Asset Ratio (MRQ)Less than10.108
Debt to Equity Ratio (MRQ)Less than10.121
Return on Equity (MRQ)Greater than0.150.035
Return on Assets (MRQ)Greater than0.050.031
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Xvivo Perfusion AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.137
Ma 20Greater thanMa 50277.850
Ma 50Greater thanMa 100279.440
Ma 100Greater thanMa 200285.115
OpenGreater thanClose275.000
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Operating Income  2,3048,90311,207-7,4053,8021,5005,302-30,463-25,161



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets2,181,091
Total Liabilities236,046
Total Stockholder Equity1,945,045
 As reported
Total Liabilities 236,046
Total Stockholder Equity+ 1,945,045
Total Assets = 2,181,091

Assets

Total Assets2,181,091
Total Current Assets826,405
Long-term Assets1,354,686
Total Current Assets
Cash And Cash Equivalents 546,088
Net Receivables 138,713
Inventory 141,604
Total Current Assets  (as reported)826,405
Total Current Assets  (calculated)826,405
+/-0
Long-term Assets
Property Plant Equipment 97,552
Goodwill 591,392
Long-term Assets Other 628,966
Long-term Assets  (as reported)1,354,686
Long-term Assets  (calculated)1,317,910
+/- 36,776

Liabilities & Shareholders' Equity

Total Current Liabilities134,488
Long-term Liabilities101,558
Total Stockholder Equity1,945,045
Total Current Liabilities
Short-term Debt 10,268
Accounts payable 124,220
Total Current Liabilities  (as reported)134,488
Total Current Liabilities  (calculated)134,488
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)101,558
Long-term Liabilities  (calculated)0
+/- 101,558
Total Stockholder Equity
Common Stock805
Retained Earnings 119,574
Other Stockholders Equity 1,824,666
Total Stockholder Equity (as reported)1,945,045
Total Stockholder Equity (calculated)1,945,045
+/-0
Other
Cash and Short Term Investments 546,088
Common Stock Shares Outstanding 31,499
Liabilities and Stockholders Equity 2,181,091
Net Debt -514,651
Net Working Capital 691,917
Short Long Term Debt Total 31,437



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-03-312011-12-31
> Total Assets 
140,875
0
114,518
108,893
113,034
117,916
127,565
131,415
209,164
195,174
201,701
202,296
202,840
201,152
204,180
205,944
340,921
346,800
349,298
340,913
529,915
528,372
538,540
541,867
576,644
578,746
586,612
601,199
644,450
657,222
634,487
644,666
620,408
1,119,096
1,150,309
1,168,139
1,149,331
1,144,377
1,542,596
1,524,570
1,584,855
1,641,499
1,733,084
1,739,869
1,788,447
2,237,108
2,181,091
2,181,0912,237,1081,788,4471,739,8691,733,0841,641,4991,584,8551,524,5701,542,5961,144,3771,149,3311,168,1391,150,3091,119,096620,408644,666634,487657,222644,450601,199586,612578,746576,644541,867538,540528,372529,915340,913349,298346,800340,921205,944204,180201,152202,840202,296201,701195,174209,164131,415127,565117,916113,034108,893114,5180140,875
   > Total Current Assets 
0
0
32,288
24,845
24,630
29,419
33,021
31,108
105,875
88,383
93,142
94,115
94,123
90,891
95,635
97,987
97,301
98,659
98,106
85,609
273,268
265,502
264,622
261,735
279,965
273,090
277,680
276,433
297,419
297,560
259,885
255,147
222,048
708,861
463,230
465,500
432,989
412,889
547,532
499,408
501,019
505,975
467,508
440,851
431,448
873,619
826,405
826,405873,619431,448440,851467,508505,975501,019499,408547,532412,889432,989465,500463,230708,861222,048255,147259,885297,560297,419276,433277,680273,090279,965261,735264,622265,502273,26885,60998,10698,65997,30197,98795,63590,89194,12394,11593,14288,383105,87531,10833,02129,41924,63024,84532,28800
       Cash And Cash Equivalents 
0
0
7,776
1,124
1,156
2,962
4,131
2,127
2,520
55,064
48,203
39,663
41,637
42,596
41,034
42,722
41,779
40,053
23,371
16,515
203,040
200,818
195,022
193,507
209,038
201,248
186,264
176,483
198,215
197,643
159,146
158,608
139,993
608,374
353,436
350,324
311,419
284,516
398,396
339,784
317,885
314,561
246,545
197,954
171,437
594,261
546,088
546,088594,261171,437197,954246,545314,561317,885339,784398,396284,516311,419350,324353,436608,374139,993158,608159,146197,643198,215176,483186,264201,248209,038193,507195,022200,818203,04016,51523,37140,05341,77942,72241,03442,59641,63739,66348,20355,0642,5202,1274,1312,9621,1561,1247,77600
       Net Receivables 
75,057
0
10,047
12,066
9,843
8,280
8,698
12,574
84,055
11,977
13,552
27,514
23,352
16,741
20,984
30,259
28,430
26,560
31,341
33,652
37,151
32,515
30,772
40,506
41,963
35,697
46,925
51,738
52,570
52,807
49,110
45,021
34,029
47,042
43,700
49,956
48,835
49,374
63,911
89,328
108,427
101,418
94,500
132,348
136,355
133,740
138,713
138,713133,740136,355132,34894,500101,418108,42789,32863,91149,37448,83549,95643,70047,04234,02945,02149,11052,80752,57051,73846,92535,69741,96340,50630,77232,51537,15133,65231,34126,56028,43030,25920,98416,74123,35227,51413,55211,97784,05512,5748,6988,2809,84312,06610,047075,057
       Other Current Assets 
816
0
11,138
12,066
9,843
8,280
10,900
12,574
84,055
11,977
18,749
27,514
23,352
16,741
26,003
30,259
28,430
26,560
40,184
33,652
37,151
32,515
38,897
40,506
41,963
35,697
55,029
51,738
52,570
52,807
56,868
45,021
34,031
47,042
50,443
49,956
48,835
49,374
71,546
89,328
108,427
101,418
4,439
0
0
0
0
00004,439101,418108,42789,32871,54649,37448,83549,95650,44347,04234,03145,02156,86852,80752,57051,73855,02935,69741,96340,50638,89732,51537,15133,65240,18426,56028,43030,25926,00316,74123,35227,51418,74911,97784,05512,57410,9008,2809,84312,06611,1380816
   > Long-term Assets 
0
0
82,230
84,048
88,404
88,497
94,544
100,307
103,289
106,791
108,559
108,181
108,717
110,261
108,545
107,957
243,620
248,141
251,192
255,304
256,647
262,870
273,918
280,132
296,679
305,656
308,932
324,766
347,031
359,662
374,602
389,519
398,360
410,235
687,079
702,639
716,342
731,488
995,064
1,025,162
1,083,836
1,135,524
1,265,576
1,299,018
1,356,999
1,363,489
1,354,686
1,354,6861,363,4891,356,9991,299,0181,265,5761,135,5241,083,8361,025,162995,064731,488716,342702,639687,079410,235398,360389,519374,602359,662347,031324,766308,932305,656296,679280,132273,918262,870256,647255,304251,192248,141243,620107,957108,545110,261108,717108,181108,559106,791103,289100,30794,54488,49788,40484,04882,23000
       Property Plant Equipment 
92
0
748
809
854
945
917
847
798
765
1,124
2,809
5,956
5,623
7,123
8,663
10,726
13,758
15,166
14,314
13,250
13,239
16,277
17,257
18,478
17,711
15,615
22,497
21,578
23,014
23,554
27,401
23,981
21,780
21,334
22,533
22,140
21,706
26,297
28,206
32,481
36,978
47,579
64,108
77,780
78,193
97,552
97,55278,19377,78064,10847,57936,97832,48128,20626,29721,70622,14022,53321,33421,78023,98127,40123,55423,01421,57822,49715,61517,71118,47817,25716,27713,23913,25014,31415,16613,75810,7268,6637,1235,6235,9562,8091,124765798847917945854809748092
       Goodwill 
0
0
3,811
3,610
3,410
3,209
3,008
2,808
2,607
2,407
2,206
2,006
1,805
1,604
3,849
3,755
65,388
65,451
65,672
65,596
65,382
65,216
65,273
65,332
65,608
65,561
65,614
65,757
65,752
65,998
65,773
66,123
65,788
65,622
223,938
227,348
225,468
226,801
460,228
467,769
498,213
525,648
625,319
626,991
653,469
645,409
591,392
591,392645,409653,469626,991625,319525,648498,213467,769460,228226,801225,468227,348223,93865,62265,78866,12365,77365,99865,75265,75765,61465,56165,60865,33265,27365,21665,38265,59665,67265,45165,3883,7553,8491,6041,8052,0062,2062,4072,6072,8083,0083,2093,4103,6103,81100
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
71
14,692
15,958
17,968
71
13,885
14,270
12,594
223
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000022312,59414,27013,8857117,96815,95814,692710000000000000000000000
       Intangible Assets 
1,465
0
5,164
76,451
78,412
79,731
86,214
89,820
94,409
98,508
97,135
95,698
94,659
93,972
93,086
92,109
154,513
155,235
158,072
161,451
165,283
170,242
176,902
182,851
196,635
204,416
214,084
222,627
245,431
258,056
272,736
283,956
293,397
302,953
400,718
413,638
427,911
441,541
465,209
486,950
514,273
532,045
552,995
570,202
590,919
601,656
0
0601,656590,919570,202552,995532,045514,273486,950465,209441,541427,911413,638400,718302,953293,397283,956272,736258,056245,431222,627214,084204,416196,635182,851176,902170,242165,283161,451158,072155,235154,51392,10993,08693,97294,65995,69897,13598,50894,40989,82086,21479,73178,41276,4515,16401,465
       Long-term Assets Other 
0
0
522
3,178
5,728
4,612
2,784
6,832
5,475
5,111
3,176
7,668
6,297
9,062
0
3,430
0
0
1
0
0
14,173
71
14,692
15,958
17,968
71
13,885
14,270
12,594
223
12,039
15,194
19,880
755
39,120
40,823
41,440
1,159
42,237
38,869
40,853
411
37,717
34,831
38,231
628,966
628,96638,23134,83137,71741140,85338,86942,2371,15941,44040,82339,12075519,88015,19412,03922312,59414,27013,8857117,96815,95814,6927114,173001003,43009,0626,2977,6683,1765,1115,4756,8322,7844,6125,7283,17852200
> Total Liabilities 
128,967
0
25,753
17,706
19,568
23,520
30,930
33,081
39,444
21,993
25,518
22,529
25,283
21,989
19,306
20,947
23,960
30,589
32,884
25,243
28,768
30,184
34,208
33,661
41,315
44,116
46,135
58,614
70,909
74,599
56,966
55,404
50,755
77,205
141,848
146,217
138,824
131,836
257,146
224,984
239,000
259,866
302,948
292,985
285,096
308,993
236,046
236,046308,993285,096292,985302,948259,866239,000224,984257,146131,836138,824146,217141,84877,20550,75555,40456,96674,59970,90958,61446,13544,11641,31533,66134,20830,18428,76825,24332,88430,58923,96020,94719,30621,98925,28322,52925,51821,99339,44433,08130,93023,52019,56817,70625,7530128,967
   > Total Current Liabilities 
124,942
0
23,721
15,294
14,969
18,799
25,658
27,687
33,928
16,355
18,758
15,647
18,279
14,863
15,581
17,156
20,145
26,732
29,840
22,110
25,604
26,988
30,896
30,359
38,016
40,821
42,573
50,482
63,425
68,038
52,599
49,147
45,281
72,924
72,248
75,681
70,301
62,612
104,519
70,539
77,361
86,369
134,896
133,301
114,364
142,066
134,488
134,488142,066114,364133,301134,89686,36977,36170,539104,51962,61270,30175,68172,24872,92445,28149,14752,59968,03863,42550,48242,57340,82138,01630,35930,89626,98825,60422,11029,84026,73220,14517,15615,58114,86318,27915,64718,75816,35533,92827,68725,65818,79914,96915,29423,7210124,942
       Short-term Debt 
0
0
9,089
106
79
5,974
6,659
11,811
15,898
0
0
0
0
0
0
0
0
0
0
22,110
25,604
26,988
0
30,359
38,016
40,821
0
50,482
63,425
68,038
3,396
6,061
45,281
72,924
3,926
4,740
4,148
3,925
4,199
3,512
4,550
4,158
5,550
133,301
114,364
9,455
10,268
10,2689,455114,364133,3015,5504,1584,5503,5124,1993,9254,1484,7403,92672,92445,2816,0613,39668,03863,42550,482040,82138,01630,359026,98825,60422,110000000000015,89811,8116,6595,974791069,08900
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,482
3,334
64,642
0
43,086
39,220
66,863
0
0
0
3,925
0
0
0
4,158
0
133,301
114,364
0
0
00114,364133,30104,1580003,92500066,86339,22043,086064,6423,33450,482000000000000000000000000000
       Accounts payable 
1,335
0
6,700
4,545
4,202
3,947
8,419
5,614
4,696
7,189
6,468
5,839
6,154
4,747
3,650
4,797
6,843
12,477
12,563
0
0
0
11,121
0
0
0
16,333
0
0
0
14,406
0
0
0
14,468
0
0
0
21,445
0
0
0
38,469
124,261
104,652
132,611
124,220
124,220132,611104,652124,26138,46900021,44500014,46800014,40600016,33300011,12100012,56312,4776,8434,7973,6504,7476,1545,8396,4687,1894,6965,6148,4193,9474,2024,5456,70001,335
       Other Current Liabilities 
123,607
0
7,932
10,643
10,688
8,878
10,580
10,262
13,334
9,166
12,290
9,808
12,125
10,116
11,931
12,359
13,302
14,255
17,277
22,110
25,604
26,988
19,775
30,359
38,016
40,821
26,240
47,148
60,091
3,396
34,797
43,086
39,220
66,863
53,854
70,941
66,153
58,687
78,574
67,027
72,811
82,211
90,877
133,301
104,652
132,611
0
0132,611104,652133,30190,87782,21172,81167,02778,57458,68766,15370,94153,85466,86339,22043,08634,7973,39660,09147,14826,24040,82138,01630,35919,77526,98825,60422,11017,27714,25513,30212,35911,93110,11612,1259,80812,2909,16613,33410,26210,5808,87810,68810,6437,9320123,607
   > Long-term Liabilities 
0
0
2,032
2,412
4,599
4,721
5,272
5,394
5,516
5,638
6,760
6,882
7,004
7,126
3,725
3,791
3,815
3,857
3,044
3,133
3,164
3,196
3,312
3,302
3,299
3,295
3,562
8,132
7,484
6,561
4,367
6,257
5,474
4,281
69,600
70,536
68,523
69,224
152,627
154,445
161,639
173,497
168,052
159,684
170,732
166,927
101,558
101,558166,927170,732159,684168,052173,497161,639154,445152,62769,22468,52370,53669,6004,2815,4746,2574,3676,5617,4848,1323,5623,2953,2993,3023,3123,1963,1643,1333,0443,8573,8153,7913,7257,1267,0046,8826,7605,6385,5165,3945,2724,7214,5992,4122,03200
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,286
2,160
1,646
746
1,522
1,632
1,874
1,387
4,455
9,605
17,872
16,070
0
016,07017,8729,6054,4551,3871,8741,6321,5227461,6462,1603,2860000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-9,089
-106
-79
-5,974
-6,659
-11,811
-15,898
0
0
0
0
0
0
0
0
0
0
-22,110
-25,604
-26,988
0
-30,359
-38,016
-40,821
0
-50,482
-63,425
-68,038
2,154
4,042
-36,635
-65,301
3,286
-4,740
-4,148
-3,925
1,522
-3,512
-4,550
-4,158
4,455
-133,301
-114,364
-9,455
-10,268
-10,268-9,455-114,364-133,3014,455-4,158-4,550-3,5121,522-3,925-4,148-4,7403,286-65,301-36,6354,0422,154-68,038-63,425-50,4820-40,821-38,016-30,3590-26,988-25,604-22,1100000000000-15,898-11,811-6,659-5,974-79-106-9,08900
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,555
3,555
3,551
0
2,215
2,889
2,719
40,150
68,376
66,877
68,478
124,522
152,813
159,765
172,110
137,130
0
152,860
150,857
0
0150,857152,8600137,130172,110159,765152,813124,52268,47866,87768,37640,1502,7192,8892,21503,5513,5553,555000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
155,169
0
0
0
173,430
0
0
0
210,460
218,958
241,021
252,819
266,517
277,861
287,282
296,526
393,969
406,464
419,891
432,845
456,551
478,236
505,496
523,498
544,510
561,574
0
0
0
000561,574544,510523,498505,496478,236456,551432,845419,891406,464393,969296,526287,282277,861266,517252,819241,021218,958210,460000173,430000155,169000000000000000000
> Total Stockholder Equity
11,908
11,908
88,765
91,187
93,466
94,396
96,635
98,334
169,720
173,181
176,183
179,767
177,557
179,163
184,874
184,997
313,096
314,406
316,414
315,670
501,147
498,707
504,332
508,206
535,329
534,630
540,477
542,585
573,541
582,623
577,521
589,262
569,653
1,041,891
1,008,461
1,021,922
1,010,507
1,012,541
1,285,450
1,299,586
1,345,855
1,381,633
1,430,136
1,446,884
1,503,351
1,928,115
1,945,045
1,945,0451,928,1151,503,3511,446,8841,430,1361,381,6331,345,8551,299,5861,285,4501,012,5411,010,5071,021,9221,008,4611,041,891569,653589,262577,521582,623573,541542,585540,477534,630535,329508,206504,332498,707501,147315,670316,414314,406313,096184,997184,874179,163177,557179,767176,183173,181169,72098,33496,63594,39693,46691,18788,76511,90811,908
   Common Stock
100
0
500
500
500
500
500
500
550
550
550
550
550
550
550
550
601
604
604
604
669
670
670
670
675
675
675
675
680
680
680
680
680
734
734
734
735
735
754
754
756
756
762
762
762
805
805
8058057627627627567567547547357357347347346806806806806806756756756756706706706696046046046015505505505505505505505505005005005005005000100
   Retained Earnings 
11,808
0
83,340
90,687
92,966
93,896
89,689
97,834
9,101
12,562
12,444
16,028
13,590
15,323
20,617
21,731
23,408
22,393
21,579
21,534
22,624
22,273
27,383
31,257
34,938
35,037
39,921
39,606
41,834
46,763
44,860
51,403
35,384
20,700
1,125
7,159
-1,782
-2,911
9,277
14,091
21,621
27,018
27,753
41,621
48,816
51,100
119,574
119,57451,10048,81641,62127,75327,01821,62114,0919,277-2,911-1,7827,1591,12520,70035,38451,40344,86046,76341,83439,60639,92135,03734,93831,25727,38322,27322,62421,53421,57922,39323,40821,73120,61715,32313,59016,02812,44412,5629,10197,83489,68993,89692,96690,68783,340011,808
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
515,753
515,767
517,084
1,007,307
1,006,784
1,006,794
1,008,023
1,008,023
1,253,330
1,253,030
1,253,905
1,253,905
1,313,839
1,313,839
1,330,421
1,763,378
0
01,763,3781,330,4211,313,8391,313,8391,253,9051,253,9051,253,0301,253,3301,008,0231,008,0231,006,7941,006,7841,007,307517,084515,767515,753000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
90,687
92,966
93,896
6,446
97,834
160,069
160,069
163,189
163,189
163,417
163,290
163,707
162,716
289,087
291,409
294,231
293,532
477,854
475,764
476,279
8,618
12,777
12,058
499,881
15,444
531,027
19,575
531,981
537,179
533,589
1,020,457
1,006,602
1,014,029
1,011,554
1,014,717
1,275,419
1,284,741
1,323,478
1,353,859
1,401,621
1,313,839
1,330,421
1,763,378
1,824,666
1,824,6661,763,3781,330,4211,313,8391,401,6211,353,8591,323,4781,284,7411,275,4191,014,7171,011,5541,014,0291,006,6021,020,457533,589537,179531,98119,575531,02715,444499,88112,05812,7778,618476,279475,764477,854293,532294,231291,409289,087162,716163,707163,290163,417163,189163,189160,069160,06997,8346,44693,89692,96690,687000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue597,542
Cost of Revenue-199,055
Gross Profit398,487398,487
 
Operating Income (+$)
Gross Profit398,487
Operating Expense-395,420
Operating Income3,0673,067
 
Operating Expense (+$)
Research Development112,765
Selling General Administrative295,876
Selling And Marketing Expenses0
Operating Expense395,420408,641
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-5,781
Net Interest Income-5,781
 
Pretax Income (+$)
Operating Income3,067
Net Interest Income-5,781
Other Non-Operating Income Expenses0
Income Before Tax (EBT)94,521-88,387
EBIT - interestExpense = 3,067
94,521
91,820
Interest Expense0
Earnings Before Interest and Taxes (EBIT)3,06794,521
Earnings Before Interest and Taxes (EBITDA)50,417
 
After tax Income (+$)
Income Before Tax94,521
Tax Provision-7,630
Net Income From Continuing Ops24,08086,891
Net Income91,820
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses594,475
Total Other Income/Expenses Net91,4545,781
 

Technical Analysis of Xvivo Perfusion AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xvivo Perfusion AB. The general trend of Xvivo Perfusion AB is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xvivo Perfusion AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Xvivo Perfusion AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 294.00 < 313.50 < 343.50.

The bearish price targets are: 266.50 > 252.50 > 217.00.

Tweet this
Xvivo Perfusion AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Xvivo Perfusion AB. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Xvivo Perfusion AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Xvivo Perfusion AB. The current macd is -1.02017228.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xvivo Perfusion AB price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xvivo Perfusion AB. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xvivo Perfusion AB price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Xvivo Perfusion AB Daily Moving Average Convergence/Divergence (MACD) ChartXvivo Perfusion AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Xvivo Perfusion AB. The current adx is 9.74721571.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Xvivo Perfusion AB shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Xvivo Perfusion AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Xvivo Perfusion AB. The current sar is 286.88.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Xvivo Perfusion AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Xvivo Perfusion AB. The current rsi is 48.14. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Xvivo Perfusion AB Daily Relative Strength Index (RSI) ChartXvivo Perfusion AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Xvivo Perfusion AB. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xvivo Perfusion AB price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Xvivo Perfusion AB Daily Stochastic Oscillator ChartXvivo Perfusion AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Xvivo Perfusion AB. The current cci is -66.02768903.

Xvivo Perfusion AB Daily Commodity Channel Index (CCI) ChartXvivo Perfusion AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Xvivo Perfusion AB. The current cmo is -3.69413878.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Xvivo Perfusion AB Daily Chande Momentum Oscillator (CMO) ChartXvivo Perfusion AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Xvivo Perfusion AB. The current willr is -66.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Xvivo Perfusion AB is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Xvivo Perfusion AB Daily Williams %R ChartXvivo Perfusion AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Xvivo Perfusion AB.

Xvivo Perfusion AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Xvivo Perfusion AB. The current atr is 8.32732146.

Xvivo Perfusion AB Daily Average True Range (ATR) ChartXvivo Perfusion AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Xvivo Perfusion AB. The current obv is 1,350,193.

Xvivo Perfusion AB Daily On-Balance Volume (OBV) ChartXvivo Perfusion AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Xvivo Perfusion AB. The current mfi is 49.41.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Xvivo Perfusion AB Daily Money Flow Index (MFI) ChartXvivo Perfusion AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Xvivo Perfusion AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Xvivo Perfusion AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Xvivo Perfusion AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.137
Ma 20Greater thanMa 50277.850
Ma 50Greater thanMa 100279.440
Ma 100Greater thanMa 200285.115
OpenGreater thanClose275.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xvivo Perfusion AB with someone you think should read this too:
  • Are you bullish or bearish on Xvivo Perfusion AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xvivo Perfusion AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Xvivo Perfusion AB

I send you an email if I find something interesting about Xvivo Perfusion AB.


Comments

How you think about this?

Leave a comment

Stay informed about Xvivo Perfusion AB.

Receive notifications about Xvivo Perfusion AB in your mailbox!